Novartis AG ADRNVS
Price$141.05Intrinsic value$123.5312% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $59.4BTTM through 31 Dec 2025
Net Income $14B+17.0% YoYTTM through 31 Dec 2025
Free Cash Flow $17.6BTTM through 31 Dec 2025

Margins

Current

Returns

30.0%ROE
12.6%ROA
21.9%ROIC

Balance Sheet Health

Debt / Equity0.62x
Current Ratio1.12x
Net Debt$17.3B
Cash & Equivalents$11.4B

Quality Metrics

Piotroski F-Score6 / 9
FCF Margin29.6%
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS
'19'20'21'22'23'24'25
FY2025: $7.15

Dividend

$4.77Per share, FY20263.38%Yield4 yrsStreak+7.2%5-yr growth

Segment Performance

SegmentRevenueYoYOutlook
Innovative Medicines$54.5B+8.0%
View details

Reaffirmed full-year 2026 guidance forecasting low single-digit net sales growth and a low single-digit decline in core operating income in constant currencies.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.